---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-037928"
form_type: "8-K"
ticker: "CVKD"
cik: "0001937993"
company_name: "Cadrenal Therapeutics, Inc."
filed_at: "2023-05-10T23:59:59+00:00"
generated_at: "2026-06-15T07:15:45.384747+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cadrenal Therapeutics reports Q1 2023 cash of $4M, Fast Track for tecarfarin

## Summary
- FDA granted Fast Track designation for tecarfarin in ESRD/AFib patients in Jan 2023.
- Completed IPO raising $7.0M gross proceeds; cash at March 31, 2023 was $4.0M.
- Q1 2023 operating expenses (ex-non-cash) were $913,653; cash expected to fund through Q2 2024.
- Plans Phase 3 ACTOR-AF trial (492 patients) as pivotal step before NDA submission.
- Market opportunity for tecarfarin estimated up to $1B annually if FDA approved.

## SEC filing metadata
- accession: 0001213900-23-037928
- form_type: 8-K
- ticker: CVKD
- cik: 0001937993
- company_name: Cadrenal Therapeutics, Inc.
- filed_at: 2023-05-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937993/000121390023037928/0001213900-23-037928-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937993/000121390023037928/ea178256-8k_cadrenal.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-037928
- JSON: https://secwatch.observer/filing/0001213900-23-037928.json
- Plain text: https://secwatch.observer/filing/0001213900-23-037928.txt

## Key facts
- Earnings Releases
  Cadrenal Therapeutics, Inc. reported preliminary financial results for the fiscal quarter ended March 31, 2023.
  - Period: the fiscal quarter ended March 31, 2023
  - Result: preliminary results
  source text: On May 10, 2023, Cadrenal Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release that included financial information for the fiscal quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1937993/000121390023037928/0001213900-23-037928-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.